{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:35:25Z","timestamp":1793885725555,"version":"4.8.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.esmoop.2024.103623","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T20:05:41Z","timestamp":1719950741000},"page":"103623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)"],"prefix":"10.1016","volume":"9","author":[{"given":"R.","family":"Olofsson Bagge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shafazand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Helgadottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rizell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wir\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lindn\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.esmoop.2024.103623_bib1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26","volume":"123","author":"Diener-West","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103623_bib2","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103623_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103623_bib4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103623_bib5","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.esmoop.2024.103623_bib6","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103623_bib7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1245\/s10434-013-3304-z","article-title":"Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit","volume":"21","author":"Olofsson","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"95","key":"10.1016\/j.esmoop.2024.103623_bib8","article-title":"Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma","author":"Ben-Shabat","year":"2015","journal-title":"J\u00a0Vis Exp"},{"issue":"16","key":"10.1016\/j.esmoop.2024.103623_bib9","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.22.01705","article-title":"Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, open-label, phase III trial (the SCANDIUM trial)","volume":"41","author":"Olofsson","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103623_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","article-title":"Molecular characteristics of immunogenic cancer cell death","volume":"15","author":"Tesniere","year":"2008","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103623_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2024.103623_bib12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fonc.2018.00570","article-title":"Isolated limb perfusion with melphalan triggers immune activation in melanoma patients","volume":"8","author":"Johansson","year":"2018","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103623_bib13","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.1401894","article-title":"Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells","volume":"194","author":"Lu","year":"2015","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103623_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3109\/02656736.2013.782428","article-title":"Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma","volume":"29","author":"Olofsson","year":"2013","journal-title":"Int J Hyperthermia"},{"issue":"24","key":"10.1016\/j.esmoop.2024.103623_bib15","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1158\/0008-5472.CAN-15-1184","article-title":"Melphalan, antimelanoma immunity, and inflammation - letter","volume":"75","author":"Martner","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103623_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1854519","article-title":"Presence of tumor-infiltrating CD8(+) T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis","volume":"9","author":"Johansson","year":"2020","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103623_bib17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103623_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2024.103623_bib19","article-title":"Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial)","volume":"40","author":"Olofsson","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103623_bib20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00270-022-03338-1","article-title":"Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: first safety and efficacy data from the phase Ib part of the Chopin trial","volume":"46","author":"Tong","year":"2023","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"16","key":"10.1016\/j.esmoop.2024.103623_bib21","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"34","key":"10.1016\/j.esmoop.2024.103623_bib22","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103623_bib23","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.21.01570","article-title":"Adaptive dosing of nivolumab\u00a0+ ipilimumab immunotherapy based upon early, interim radiographic assessment in advanced melanoma (the ADAPT-IT study)","volume":"40","author":"Postow","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2024.103623_bib24","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.3390\/cancers13184726","article-title":"Meta-analysis of isolated hepatic perfusion and percutaneous hepatic perfusion as a treatment for uveal melanoma liver metastases","volume":"13","author":"Bethlehem","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103623_bib25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study","volume":"7","author":"Heppt","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.103623_bib26","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2022.40.16_suppl.9510","article-title":"FOCUS phase 3 trial results: percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301\/301A)","volume":"40","author":"Zager","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924013929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924013929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T17:31:33Z","timestamp":1728063093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924013929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2059702924013929"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103623","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103623"}}